EN DE
STOCK COMPARISON

Orphazyme A/S vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Orphazyme A/S (OZYMF) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 24, 2026.

As of Sep 24, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Orphazyme A/S trades at $90.00 versus a fair value of $54.75 (-39%), while Vertex Pharmaceuticals trades at $515 versus $566 (+10%).
Orphazyme A/S
OZYMF · USD · Health Care
-39%
upside to fair value
overvalued
Price$90.00
Fair Value$54.75
Quality51/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
+10%
upside to fair value
undervalued
Price$515
Fair Value$566
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Orphazyme A/SVertex Pharmaceuticals
Valuation
n/aP/E (TTM)30.6×
12.15×P/S (TTM)10.88×
0.20×P/B7.12×
n/aEV/EBITDA25.8×
n/aPEG1.72×
−39.2%Fair value upside+10.0%
Profitability
n/aOperating margin38%
n/aEBIT margin trend (5Y)0.86×
-5%Return on equity24%
-7%Return on assets12%
Growth
0%Revenue growth (YoY)8%
n/aAvg. growth/yr (3Y)10.6%
n/aAvg. growth/yr (5Y)14.2%
n/aValue creation/yr+13.5%
Balance & size
n/aInterest coverage (EBIT/interest)357.9×
0.14×Debt / equity0.03×
$4MMarket cap$133B
weakGrowth qualityhealthy

Vertex Pharmaceuticals leads: 1 to 5 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Orphazyme A/Sof which business quality 51 · market factors 56 Vertex Pharmaceuticalsof which business quality 77 · market factors 75
ProfitabilityMargins and returns on capital today
1
72
Quality GrowthAre margins and returns improving?
32
65
CashflowEarnings quality: real cash, not paper profit
50
79
Fin. StrengthBalance sheet, leverage, solvency risk
54
92
InvestmentDisciplined investing over empire-building
100
58
Low VolatilityCalm price path (market factor)
100
85
MomentumPrice trend over the last 3–12 months (market factor)
40
65
52W MomentumDistance to the 52-week high (market factor)
33
81
Net IssuanceShare count: buybacks or dilution?
100
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyOrphazyme A/SPrice $90.00Vertex PharmaceuticalsPrice $515
DCF Modelsn/a-12%close to the price$453
Earnings-Basedn/a0%close to the price$516
Multiplesn/a-46%below the price$278
Asset-Based+231%above the price$298-90%below the price$49.27
Growth DCFn/a-32%below the price$349
Economic Profitn/a-53%below the price$245
Growth Earningsn/a+34%above the price$692
Minimum+231%above the price$298-90%below the price$49.27
Maximum+231%above the price$298+34%above the price$692
Median+231%above the price$298-32%below the price$349
Geometric mean+231%above the price$298-43%below the price$294

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Orphazyme A/S: 0 of 1 models see the stock below the current price.

Vertex Pharmaceuticals: 17 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Orphazyme A/S
Price $90.00
Fair Value $54.75
Bear $36.14Bull $68.44
Vertex Pharmaceuticals
Price $515
Fair Value $566
Bear $340Bull $1,226

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Orphazyme A/S · Health Care

Quality score51 · below median
Fair value upside-39% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside+10% · above median

Bottom line

As of Sep 24, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the more attractively valued of the two: Orphazyme A/S trades at $90.00 versus a fair value of $54.75 (-39%), while Vertex Pharmaceuticals trades at $515 versus $566 (+10%).

Vertex Pharmaceuticals has the higher quality score (79/100).

Open Vertex Pharmaceuticals live analysis →
Orphazyme A/S · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Orphazyme A/S

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Vertex Pharmaceuticals

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.